Literature DB >> 17949824

Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression.

M Motta1, R Imbesi, M Di Rosa, F Stivala, L Malaguarnera.   

Abstract

Increasing evidence supports a propensity towards inflammation in Alzheimer's disease (AD) pathogenesis. In our previous studies we observed high levels of IL-16, IL-18 and TGF-beta1 mRNA expression in monocyte-macrophages of the peripheral blood of AD patients. The aim of this investigation was to determine the plasma levels of IL-12, IL-16, IL-18 and TGF-beta1 in AD patients at different stages of the disease and to correlate the production of these cytokines with the disease progression. The levels of IL-12, IL-16, IL-18 and TGF-beta1 resulted higher in AD-mild patients, were slightly lower in AD-moderate patients, whereas no significant difference was observed between AD-severe patients and non-demented age-matched subjects. The correlation values between cytokine plasma levels were dependent on the disease progression. Our data indicate that plasma levels of these inflammatory molecules follow the degree of AD suggesting a gradual decline of immune responsiveness in AD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17949824     DOI: 10.1016/j.imlet.2007.09.002

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  60 in total

1.  Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain.

Authors:  Sara L Montgomery; Michael A Mastrangelo; Diala Habib; Wade C Narrow; Sara A Knowlden; Terry W Wright; William J Bowers
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

2.  Age-dependent changes on TGFβ1 Smad3 pathway modify the pattern of microglial cell activation.

Authors:  Juan E Tichauer; Betsi Flores; Bernardita Soler; Laura Eugenín-von Bernhardi; Gigliola Ramírez; Rommy von Bernhardi
Journal:  Brain Behav Immun       Date:  2013-12-29       Impact factor: 7.217

Review 3.  Innate immune activation in Alzheimer's disease.

Authors:  Ming-Ming Wang; Dan Miao; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

4.  Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology.

Authors:  Kaori Morimoto; Juri Horio; Haruhisa Satoh; Lucia Sue; Thomas Beach; Seizaburo Arita; Ikuo Tooyama; Yoshihiro Konishi
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 5.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

Review 6.  The role of inflammasome in Alzheimer's disease.

Authors:  Li Liu; Christina Chan
Journal:  Ageing Res Rev       Date:  2014-02-19       Impact factor: 10.895

Review 7.  Alzheimer's disease and type 2 diabetes: multiple mechanisms contribute to interactions.

Authors:  Anusha Jayaraman; Christian J Pike
Journal:  Curr Diab Rep       Date:  2014-04       Impact factor: 4.810

8.  Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults.

Authors:  Niklas Mattsson; Philip Insel; Rachel Nosheny; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Duygu Tosun; Michael Weiner
Journal:  Neurobiol Aging       Date:  2013-10-01       Impact factor: 4.673

9.  TNF-related apoptosis-inducing ligand level in Alzheimer's disease.

Authors:  Sermin Genc; Mehtap Yuksel Egrilmez; Erdem Yaka; Zahide Cavdar; Leyla Iyilikci; Gorsev Yener; Kursad Genc
Journal:  Neurol Sci       Date:  2009-03-18       Impact factor: 3.307

Review 10.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.